Dupuytren's Disease Therapeutics Market size was valued at USD 1 billion in 2024 and is anticipated to reach USD 4.6 billion by the end of 2037, rising at a CAGR of 12.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of dupuytren’s disease therapeutics is evaluated at USD 1.1 billion.
Advancements in non-invasive treatments, complemented by increasing patient awareness, are some of the major drives of the dupuytren’s disease therapeutics market. Industry players continue to develop and enhance therapeutic options targeting the cause of this condition. For instance, effective injections containing collagenase are used for early-stage treatments, which further drives the adoption. Initiatives, including public awareness campaigns, are driving market growth as more patients seek treatment options at an earlier stage. Furthermore, an aging global population prone to Dupuytren’s disease is anticipated to contribute to increased demand.
Government support through health policies focused on furthering research and development of treatments for rare and chronic diseases is also driving dupuytren’s disease therapeutics market expansion. For example, government-led programs are improving access to healthcare solutions in various countries for Dupuytren's disease. The U.S. National Institutes of Health have supported research programs aimed at gaining better insights into fibrotic diseases to offer more therapeutic alternatives. These initiatives, combined with emerging treatments from key industry players, make for a healthy and promising landscape for continued progress in Dupuytren's disease therapeutics industry.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.5% |
|
Base Year Market Size (2024) |
USD 1 billion |
|
Forecast Year Market Size (2037) |
USD 4.6 billion |
|
Regional Scope |
|
Type, (I, II, III)
The Type II segment is anticipated to dominate dupuytren’s disease therapeutics market share of around 52% by the end of 2037. Type II is dominating as most of Dupuytren's patients are affected by this condition. Furthermore, the growth is accelerated by the effective management of mid-stage symptoms with targeted therapeutics before severe contracture occurs. In July 2022, a study on combining aponeurotomy with adipose tissue grafting to reduce recurrence rates highlighted demand in this segment, as treatments for Type II cases are essential in minimizing disease progression. Furthermore, ongoing research initiatives continue to improve mid-stage intervention strategies, solidifying Type II’s market dominance.
Therapeutics (Collagenase Injection, Steroids, Immune-modulators)
In dupuytren’s disease therapeutics market, collagenase injection segment is set to hold revenue share of more than 54.2% by 2037 due to its non-invasive method and high patient compliance rates. Collagenase injections break down collagen build-up in affected areas, making the treatment effective without surgery. In February 2023, Endo's ‘Man with a Plan’ campaign emphasized awareness of collagenase treatments for related conditions, noting that this segment of non-invasive Dupuytren's treatment plays a vital role. With a strong preference for non-invasive treatments, collagenase injections continue to gain widespread acceptance, making them an important segment of dupuytren's disease therapeutics market.
Our in-depth analysis of the dupuytren’s disease therapeutics market includes the following segments:
|
Type |
|
|
Therapeutics |
|
|
Distribution Channel |
|
Europe Market Analysis
Europe dupuytren’s disease therapeutics market is likely to capture revenue share of over 42.5% by 2037. This growth results from increased healthcare expenditure and a robust focus on managing chronic diseases in Europe. Healthcare policies in most countries in Europe favor treatments for fibrotic diseases, facilitating the adoption of non-surgical treatments and ensuring easy patient access to developing therapies. Europe pipeline of advanced Dupuytren's solutions is also bolstered by partnerships with research institutions, driving market growth.
A key player in Europe, Germany finances research on rare diseases and supports the development of Dupuytren's treatments through robust healthcare policies and research funding. In addition, several pharma companies are solidifying their market position in Germany, strengthening their focus on innovative Dupuytren solutions. Germany’s support for non-invasive treatments and early intervention strategies underpins its role in healthcare advancements. German institutions also participate in clinical trials that accelerate early access to breakthrough treatments.
France is another strong market for Dupuytren's therapeutics, supported by government investments in healthcare technologies. According to the European Health Data Space recommendations, improving communication and patient support systems is key to tackling chronic disease adherence challenges, a focus area for France healthcare system. Such advancements strengthen France position in Dupuytren's disease therapeutics market. The government also awards grants supporting innovative treatment research, allowing patients to access advanced therapies.
Asia Pacific Market Analysis
Asia Pacific dupuytren’s disease therapeutics market is poised to register around 11.5% growth till 2037 due to rising healthcare expenditure and improved healthcare facilities in underserved regions. This growth boosts demand for fibrotic disease treatments in a region with aging demographics and high awareness of Dupuytren's disease. Enhanced healthcare infrastructure in urban areas also facilitates access and distribution of advanced therapies.
China is an emerging market for Dupuytren's disease therapies, bolstered by government policies promoting healthcare innovation and significant M&A activity in its life sciences and healthcare (LSHC) sector. In 2021, M&A transactions in China’s LSHC industry reached 263 deals, marking a 72-deal increase over 2020 and totaling a disclosed value of USD 28 billion, an impressive year-on-year increase of 27.9%. Over half of the 109 deals valued at over USD 100 million each were concentrated in the biotech and drug sectors, reflecting substantial investment in healthcare advancements.
Awareness and Government Health Initiatives in India for unmet medical needs create significant growth opportunities. The Ministry of Health and Family Welfare started the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) to integrate chronic disease interventions into the public health delivery system. This would encourage healthy lifestyle habits and early diagnosis to reduce the growing burden of non-communicable diseases.
The market for dupuytren's disease therapeutics is highly competitive; major players are continuously innovating to capture market share. Key players include Bristol Myers Squibb, Endo International plc, AstraZeneca PLC, and Bayer AG, all leveraging strong R&D capabilities to improve therapeutic options. These companies focus on non-invasive solutions, meeting patient needs, capturing growth in emerging markets, and staying ahead of regulatory changes. Bristol Myers Squibb's acquisition of Karuna Therapeutics in March 2024 highlights the intensity of competition as companies expand their portfolios to meet the demand for diverse therapies. This competitive scenario is likely to drive further strategic investments to address the evolving needs of Dupuytren's disease therapeutics market.
Here are some leading players in the dupuytren's disease therapeutics market:
Author Credits: Rajrani Baghel
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?